D2 Pharma Consulting launches interactive Web site
ST. CHARLES, Mo. D2 Pharma Consulting on Wednesday launched its new interactive Web site — www.D2Rx.com. The Web site will integrate a “D2Rx Blog” with up-to-date industry information focused on keeping pharmaceutical and biotech executives current with industry information.
“We believe it’s our highly experienced, hands-on approach that differentiates us from similar service providers,” stated Dean Erhardt, D2 principal.
D2 provides outsourced solutions to emerging and established companies for the commercialization, distribution and marketing of pharmaceuticals, medical devices and biotech pharmaceuticals. Together with their strategic partners, D2 offers commercialization services for the clients’ approved products across the traditional, medical device and specialty pharmaceutical categories.
“D2 has the experience and knowledge to facilitate the commercialization process for the emerging BioPharma and Pharma companies,” stated fellow D2 principal Dan Steiber. “Our site is designed to assist both established and emerging organizations on key issues that may impact their commercialization efforts.”
Exsulin Corp. releases clinical trial results for investigational diabetes drug
MINNEAPOLIS Results of a mid-stage clinical trial of a drug designed to restore the ability of the pancreas to produce insulin have appeared online in the journal Diabetes/Metabolism Research and Reviews, the drug’s manufacturer has announced.
Exsulin Corp. said it planned to move forward immediately on Exsulin (INGAP peptide), designed for use in patients with Type 1 and Type 2 diabetes.
“Since the landmark discovery of insulin in 1921, only incremental progress has been made in insulin therapy, which remains difficult and hazardous – particularly for people with [Type 1 diabetes],” Exsulin Corp. founder and chairman G. Alexander Fleming said in a statement. “These study results are very encouraging that Exsulin therapy could restore normal insulin secretion, which would allow insulin-dependent [Type 1 diabetes] and [Type 2 diabetes] patients to achieve normal glucose control while decreasing or ending their dependence on insulin treatment.”
Insulet Corp. appoints new chief commerical officer
BEDFORD, Mass. A company that develops insulin-pump technology without tubing, such as the OmniPod Insulin Management System, has created a new executive position.
Insulet Corp. announced this week the appointment of Peter Devlin as chief commercial officer, placing Devlin in charge of the company’s sales, marketing, business development, clinical research and customer care operations.
“Peter brings a distinguished track record in the diabetes and medical device industries, and we are extremely pleased to have him join Insulet’s management team,” Insulet president and CEO Duane DeSisto said in a statement.
Devlin previously worked as divisional VP global strategic marketing for diabetes care at Abbott Labs for 11 years.